Endometriosis Trial, Recruiting NCT05739123 Sponsor: Sumitomo Pharma Switzerland GmbH Condition: Endometriosis
Back to Endometriosis

Endometriosis Trial, Recruiting

NCT05739123
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman of any age
  • You are currently pregnant or have been recently pregnant
  • You agree to take part in the study
  • You give permission for your doctor(s) or healthcare provider(s) to share your health information with the registry
  • (Group 1 only) You received at least one dose of a medicine containing relugolix at any point during your pregnancy
  • (Group 2 only) You have been diagnosed with a condition that relugolix is sometimes prescribed for, but you did not take any relugolix-containing medicine during your pregnancy

Who may not be able to join:

  • Your pregnancy has already ended before you first make contact with the study team (you may still be enrolled but your data would be analysed separately)
  • You were exposed during pregnancy to medicines known to cause birth defects, or to experimental/investigational medicines (your data would be analysed separately)
  • You are unable to be contacted for follow-up during the study (your data would be analysed separately)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 650-278-8743

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Sumitomo Pharma Switzerland GmbH
Registry
ClinicalTrials.gov
Start date
8 May 2023
Est. completion
1 May 2033

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Major Congenital Malformation (MCM)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov